control sample, small sample and reagent volume requirements, and automatic determination of a number of dlagnostically useful variables (including relative fibrinogen content) from the data recorded in a single run. Also, the system is shown to give results that correlate well with those obtained by conventional techniques for determination of prothrombin time.
AddItional Keyphras.s: prothrombin-time determination

#{149}
fibrinogen measurement #{149} parallel analysis #{149} photoelectric coagulation detector #{149} pediatric application #{149} the clotting process #{149} rate of fibrin formation Determination of plasma coagulation time by manual techniques is beset by many problems (1, 2) . The analyst is required to make a largely subjective decision as to the instant a gel has formed within the sample. Many instrumental techniques have been devised to reduce or eliminate the subjective element of clot endpoint location (3) (4) (5) . Of these, instruments monitoring the change in optical property upon coagulation have been among the most successful. The proteolytic enzyme, thrombin (EC 3.4.21.5), generated by a complex sequence of reactions, acts upon the protein substrate fibrinogen to form a fibrin polymer gel. During this polymerization, a corresponding increase in light-scatter and a decrease in light transmittance occur within the sample. This phenomenon was first noted by Kugelmass (6) and was later used by Baldes and Nygaard (7) as a convenient clinical measure of coagulation time. The information inherent in the optical record of the clotting process has been studied in detail by Deutsch (8) of a number of diagnostically useful variables from the data of a single run, and all of the variables may be referenced to the on-board control plasma. Another significant advantage is the small volume requirement of the analyzer (only 40 sl of sample is required for measurement of prothrombin-time); this may be useful in the diagnosis of coagulation abnormalities in newborn infants, and in the analysis for specific clotting factor deficiencies where the use of rare congenitally-deficient plasma is required as a substrate (13).
Methods
Unless otherwise noted, prothrombin times were determined by using "Simplastin" (General Diagnostics, Morris Plains, N. J. 07950) as the thromboplastin reagent. For the data presented in Figures 5, 6, and 9, Citrated Normal Plasma (Dade Division, American Hospital Supply Corp., Miami, Fla. 33152) was used; it is specified by the manufacturer to contain 240-250 mg of fibrinogen per deciliter after reconstitution.
With the CFA technique, the sample and reagent loading parts of the rotor are charged with 40 l of plasma and 80 l of thromboplastin, respectively.
The samples were brought to the incubation temperature (30 #{176}C, except for the data in Calif. 92626). The samples were coded, and the PT and PR were recorded; the remainder of the plasma was quickly frozen for later analysis by our laboratories.
About half the samples were thawed one week and the other half were thawed the following week. The freshly thawed samples were divided into two aliquots, one to be analyzed on the CFA, the other to be analyzed simultaneously in our medical laboratories with a fibrin switch instrument (the Fibrometer; BBL, Division of BioQuest, Cockeysville, Md. 21030).
With both instruments we used the same lot number of Simplastin thromboplastin reagent and the same control plasma. 
Results and Discussion
I
MultiparametriC Analysis
There is a great deal of information inherent in the continuous monitoring of the light scatter of a sample during coagulation.
In addition to the turbidity of a sample and its clotting time, it is possible to estimate the fibrinogen content, rate of fibrin formation, and clot lysis time of the sample (8, 9, 21) .
Clotting time. The variation of the computed ratio of slope with the dilution of plasma is shown in Figure 9 . 
